Neurocompute Narrative Velocity Map
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative
Velocity Map

Explore the Parkinson’s research intelligence diagram before entering the Neurocompute platform.

NC
Neurocompute
AI Parkinson’s Intelligence Terminal
RESEARCH PAPER

Personalized metabolite biomarker predictions reveal heterogeneous characteristics of Parkinson's disease.

PMID
42014729
Journal
NPJ Parkinson's disease
Publication Date
2026-04-21
Grade
D

AI Summary

Using genome-scale metabolic models and the TAMBOOR algorithm, the study predicts patient-specific metabolite secretion changes in Parkinson’s disease, identifies consensus and cluster-specific biomarkers (including dopamine, salsolinol, vitamin D3, retinal, melatonin, biliverdin), and stratifies…

Why It Matters

By uncovering heterogeneous, patient-level metabolic signatures and candidate biomarkers that intersect known PD-related pathways and potentially modifiable targets, the work can inform biomarker-driven patient stratification and hypothesis-driven therapeutic or diagnostic development, although…

Abstract

Understanding the heterogeneous nature of Parkinson's disease is crucial for improving diagnostic and treatment strategies that benefit distinct patient subgroups. Genome-scale metabolic models (GEMs) comprising biochemical reactions and corresponding genes provide powerful frameworks for such investigations when integrated with omics data. Here, we predicted patient-specific metabolite secretion patterns in the form of oversecretion/undersecretion by the TrAnscriptome-based Metabolite Biomarkers by On-Off Reactions (TAMBOOR) algorithm, which links gene expression changes to metabolites through GEMs. We first identified consensus PD biomarkers, and, subsequently stratified patients into three metabolically distinct clusters based on predicted secretion patterns. Consensus biomarkers included both well-known markers, such as dopamine and eumelanin, and additional metabolites, like salsolinol, vitamin D3, and retinal, with potential roles in PD mechanism and symptoms. A subset of the predictions also indicated that some well-known characteristics may not be consistently exhibited in all patients. Furthermore, certain metabolites like melatonin, and biliverdin, though not identified by the consensus approach, showed distinct secretion patterns across patient clusters. Our study emphasizes the importance of individual-level analysis, which has a high potential to investigate heterogeneity in the disease metabolism. Furthermore, it gives insights into the ways of patient classification that can guide more effective diagnostic and treatment strategies.

Score Breakdown

AI Score
68.0
Base Score
55.5
Rank Score
53.2
Narrative Velocity
-
AI Confidence
-
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic
Full Neurocompute Infographic